Personalized medicine and pay-for-performance: should pharmaceutical firms be fully penalized when treatment fails?
-
1
Universidad de La Rioja
info
Aldizkaria:
PharmacoEconomics
ISSN: 1170-7690
Argitalpen urtea: 2018
Mota: Artikulua
Beste argitalpen batzuk: PharmacoEconomics
Gordailu instituzionala:
lock_openSarbide irekia
Postprint